HSBC Holdings
IBRX icon

HSBC Holdings’s ImmunityBio IBRX Stock Holding History

HSBC Holdings’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-86,141
Closed -$168K – 3062
2025
Q4 		$168K Hold
86,141
– – ﹤0.01% 2721
2025
Q3 		$211K Buy
86,141
+46,900
+120% +$121K ﹤0.01% 2473
2025
Q2 		$103K Sell
39,241
-3,163
-7% -$8.51K ﹤0.01% 2844
2025
Q1 		$126K Buy
42,404
+25,564
+152% +$77.5K ﹤0.01% 2747
2024
Q4 		$43.9K Buy
+16,840
New +$70.2K ﹤0.01% 3007
2024
Q3 		– Sell
-11,545
Closed -$73.8K – 3057
2024
Q2 		$73.8K Buy
11,545
+999
+9% +$6.59K ﹤0.01% 2784
2024
Q1 		$56.6K Buy
+10,546
New +$47.8K ﹤0.01% 2925

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HSBC Holdings's IBRX Position: Q1 2026 in Review

HSBC Holdings sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 86,141 shares — an estimated $168K sold.

HSBC Holdings first reported a position in IBRX in Q1 2024 and held it in 7 quarters. The position peaked at $211K in Q3 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • HSBC Holdings reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • HSBC Holdings sold 86,141 ImmunityBio shares in Q1 2026, an estimated $168K.
  • HSBC Holdings first reported a position in ImmunityBio in Q1 2024 and held it in 7 quarters.
  • HSBC Holdings's ImmunityBio position peaked at $211K in Q3 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.